Trial Profile
Randomized, Double-masked, Placebo-controlled Evaluation of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Feb 2021
Price :
$35
*
At a glance
- Drugs Netarsudil (Primary)
- Indications Ocular hypertension
- Focus Therapeutic Use
- 11 Jul 2019 Status changed from active, no longer recruiting to completed.
- 21 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 26 Jan 2018 Status changed from not yet recruiting to recruiting.